De Novo device
Ellipsys Vascular Access System (Ellipsys System)
Avenu Medical · Percutaneous Catheter For Creation Of An Arteriovenous Fistula For Hemodialysis Access (PQK, Class II) · First FDA decision Jun 22, 2018, newest Aug 9, 2019Kidney failure and dialysisVascular access
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
De Novo pathway
Device trials
6
Naming "Ellipsys"
MAUDE reports
74
Brand "Ellipsys", since 2015
PubMed studies
42
Mentioning "Ellipsys"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Ellipsys Vascular Access System (Ellipsys System)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
K191114 · Decided Aug 9, 2019 · 105 days after receipt
Device type: Percutaneous Catheter For Creation Of An Arteriovenous Fistula For Hemodialysis Access (PQK) · Cardiology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Non-Invasive Peripheral Venous Vascular and Hemodialysis Access StudiesLocal determinationIn effectL35751WPS Insurance CorporationUpdated Feb 20, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Ellipsys", any status and sponsor, newest update first.
- Comparing Surgical and Endovascular Arteriovenous Fistula CreationActive, not recruiting
University of California, Los AngelesAcademic, hospital or other
NCT05654103 · 90 participants (planned) · Start Nov 20, 2024 · Primary completion Oct 2026
Device: endoAVF · For: End Stage Renal Disease on Dialysis
Sites: Los Angeles, California; Pittsburgh, Pennsylvania
5 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Ellipsys", and for the whole product code for context.
This brand
74 reports: 10 malfunction, 64 injury, 0 death
Whole product code PQK
492 reports: 273 malfunction, 212 injury, 7 death
Newest reports for this brand
- Ellipsys CatheterMalfunction
3014251914-2026-00001 · Received Aug 4, 2026 · Event dated Jun 25, 2026
Device type: Percutaneous Catheter For Creation Of An Arteriovenous Fistula For Hemodialysis Access (PQK)
Device problem as coded: Mechanical Jam
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Ellipsys"[tiab]. The summary above synthesizes these.
- Technical aspects of percutaneous endovascular arteriovenous fistula creation with the Ellipsys® Vascular Access System. Preliminary results after 16 patients.
Liebetrau D, Zerwes S, Kerndl H, et al. · Langenbecks Arch Surg · 2023
- Comparison of surgical versus percutaneously created arteriovenous hemodialysis fistulas.
Harika G, Mallios A, Allouache M, et al. · J Vasc Surg · 2021Comparative Study
- Gracz fistula is a feasible option after two failed percutaneous arteriovenous fistulae.
Shahverdyan R, Konner K, Matoussevitch V · J Vasc Access · 2023Case Reports
- Endovascular Arteriovenous Fistula Creation: A Review.
Tyagi R, Ahmed SS, Navuluri R, et al. · Semin Intervent Radiol · 2021Review
- Endovascular Versus Surgical Arteriovenous Fistulas: A Systematic Review and Meta-analysis.
Malik MH, Mohammed M, Kallmes DF, et al. · Kidney Med · 2022
- Anatomical Feasibility of Percutaneous Arteriovenous Fistula Formation in Korea.
Moon KY, Jang EJ, Lee SH, et al. · Vasc Endovascular Surg · 2024Comparative Study
- Long Term Results of a Comparative Study of Percutaneous and Surgically Created Proximal Forearm Arteriovenous Fistulae.
Shahverdyan R, Mehta TI, Inston N, et al. · Eur J Vasc Endovasc Surg · 2025Comparative Study
- Initial Outcomes Following Introduction of Percutaneous Arteriovenous Fistula Program with Comparison to Historical Surgically Created Fistulas.
Osofsky R, Byrd D, Reagor J, et al. · Ann Vasc Surg · 2021Comparative Study
- Comparison of Outcomes of Percutaneous Arteriovenous Fistulae Creation by Ellipsys and WavelinQ Devices.
Shahverdyan R, Beathard G, Mushtaq N, et al. · J Vasc Interv Radiol · 2020Comparative Study
- Percutaneous arteriovenous fistula creation.
Nelson PR, Mallios A, Randel M, et al. · Semin Vasc Surg · 2021Review
- Initial 6-month quality review of a percutaneous endovascular arteriovenous fistula program.
Sultan S, Langsfeld M, Chavez L, et al. · J Vasc Access · 2021
- Endovascular Arteriovenous Fistula Creation-Review of Current Experience.
Mallios A, Malik J, Jennings WC · Diagnostics (Basel) · 2022Review
Other devices of this type
Also filed under product code PQK.
- WavelinQ Plus EndoAVF SystemC.R. Bard, Inc. · 510(k) 2019
- WavelinQ 4F EndoAVF SystemC.R. Bard, Inc. · 510(k) 2019
- everlinQ endoAVF SystemTva Medical, Inc. · De Novo 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.